NCT03310541: AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: AKT
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have AKT1, AKT2, or AKT3 mutations
Exclusions: Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring steroids- see trial for details

Comments are closed.

Up ↑